Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 26

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 26
---
 accompanying prospectus may be made
available in electronic format on a website maintained
by Dawson James, and Dawson James may distribute this prospectus supplement
and the accompanying prospectus electronically.

The foregoing does not purport
to be a complete statement of the terms
and conditions of the Sales Agreement. A copy of the Sales
Agreement is included as an exhibit to our Current
Report on Form 8-K that will be filed with the
SEC and incorporated by reference into
the registration statement of which this prospectus
supplement and the accompanying prospectus form a part. See “Whe re You Can F ind Mo re Infor mation” and “Incorporation of Certain Information By Ref e rence”.

Our Common Stock is listed
on Nasdaq under the symbol “LNAI.”

Other than in the United States,
no action has been taken by us or Dawson James that would
permit a public offering of the securities offered
by this prospectus supplement in any jurisdiction
where action for that purpose is required. The securities offered
by this prospectus supplement may not be offered
or sold, directly or indirectly,
nor may this prospectus supplement or any other
offering material or advertisements
in connection with the offer
and sale of any such securities be distributed
or published in any jurisdiction, except under circumstances
that will result in compliance with
the applicable rules and regulations of that jurisdiction.
Persons into whose possession this prospectus
supplement comes are advised to inform themselves about and to
observe any restrictions relating to the offering
and the distribution of this prospectus supplement.
This prospectus supplement does not constitute an offer to sell or a solicitation
of an offer to buy any securities offered by
this prospectus supplement in any jurisdiction where any
such offer or a solicitation is unlawful.

Other Relationships

Dawson James and
certain of its affiliates have engaged in, and
may in the future engage in, investment banking
and other commercial dealings in the ordinary
course of business with us or our affiliates.
Dawson James and such affiliates
have received, or may in the future receive, customary fees and expenses for these transactions.
In addition, in the ordinary course of its various
business activities, Dawson James and its
affiliates may make or hold a broad array of investments
and actively trade debt and equity securities
(or related derivative securities) and
financial instruments (which may include bank loans) for their
own account and for the accounts of their customers